Focus on Type 1 Gaucher Disease: Improving Outcomes Through Early Recognition, Accurate Diagnosis, and Optimal Management

Activity Description & Educational Objectives

In this activity, experts in type 1 Gaucher disease discuss the importance of early recognition, accurate diagnosis, and appropriate management in order to improve outcomes in patients affected by this genetic disorder.

Upon completion of this activity, participants will be able to:

• Discuss the prevalence, classification, and symptomology of Gaucher disease
• Employ appropriate tests to ensure correct diagnosis of Gaucher disease
• Evaluate current and emerging treatment strategies for the management of Gaucher disease
• Apply appropriate diagnostic, monitoring, and treatment strategies for the optimal management of Gaucher disease

Target Audience

This activity has been designed to meet the educational needs of hematologists, pediatric hematologists, hematologist-oncologists, pediatric hematologist-oncologists, gastroenterologists, pediatric gastroenterologists, pediatricians, nurses, and other clinicians involved in the management of type 1 Gaucher disease.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: October 17, 2012 - October 16, 2013
Time to Complete: 45 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Interviewee

Neal J. Weinreb, MD, FACP
Voluntary Associate Professor of Genetics
Dr. John T. Macdonald Foundation
Department of Human Genetics
University of Miami Miller School of Medicine
Miami, Florida
University Research Foundation for Lysosomal Storage Diseases
Boca Raton, Florida

Neal J. Weinreb, MD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant for Genzyme Corporation, a Sanofi company; Pfizer Inc; Protalix Biotherapeutics; and Shire/HGT.

Grant/Research Support from Genzyme Corporation, a Sanofi company and Shire/HGT.

Speakers Bureau participant with Actelion Pharmaceuticals US, Inc; Genzyme Corporation, a Sanofi company; and Shire/HGT;

Interviewees

Joel Charrow, MD
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Head, Division of Genetics, Birth Defects and Metabolism
Ann and Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois

Joel Charrow, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Genzyme Corporation, a Sanofi company; Shire; and Synageva BioPharma.

Speakers Bureau participant with Genzyme Corporation, a Sanofi company and Shire.

Gregory A. Grabowski, MD
The A. Graeme Mitchell Chair in Human Genetics
Professor and Director, Division of Human Genetics
Cincinnati Children's Hospital and Medical Center
University of Cincinnati
Cincinnati, Ohio

Gregory A. Grabowski, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Amicus Therapeutics, Inc.; Genzyme Corporation, a Sanofi company; Pfizer Inc; Protalix Biotherapeutics; Shire/HGT; and Synageva BioPharma.

Grant/Research Support from Shire/HGT.

Other Financial or Material Support from Shire/HGT in the form of royalties/patents.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5196-13-T.

Nurses

The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by IAHB and PVI, PeerView Institute for Medical Education. Maximum of 0.75 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

This CME/CNE activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by the Institute for Advancement of Human Behavior.

This activity is supported by educational grants from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.